Epidemics of seasonal influenza viruses cause considerable morbidity and mortality each year. Various types and subtypes of influenza circulate in humans and evolve continuously such that individuals at risk of serious complications need to be vaccinated annually to keep protection up to date with circulating viruses. The influenza vaccine in most parts of the world is a trivalent vaccine, including an antigenically representative virus of recently circulating influenza A/H3N2, A/H1N1, and influenza B viruses. However, since the 1970s influenza B has split into two antigenically distinct lineages, only one of which is represented in the annual trivalent vaccine at any time. We describe a lineage selection strategy that optimizes protection against influenza B using the standard trivalent vaccine as a potentially cost effective alternative to quadrivalent vaccines.

Decision tree, Hedging, Influenza B, Quadrivalent, Trivalent vaccine, Vaccine strain selection
dx.doi.org/10.1016/j.vaccine.2016.01.042, hdl.handle.net/1765/91922
Vaccine
This work was funded by the European Commission 7th Framework Programme; grant id fp7/223498 - European management platform for emerging and re-emerging infectious disease entities (EMPERIE), This work was funded by the European Commission 7th Framework Programme; grant id fp7/278976 - ANTIcipating the Global Onset of Novel Epidemics (ANTIGONE)
Department of Virology

Mosterín Höpping, A, Fonville, J.M, Russell, C.A, James, S.L, & Smith, D.J. (2016). Influenza B vaccine lineage selection-An optimized trivalent vaccine. Vaccine, 34(13), 1617–1622. doi:10.1016/j.vaccine.2016.01.042